Company intelligence / Profile preview
NERx Biosciences
Indianapolis, Indiana, USAnerxbiosciences.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
No clinical results yet; preliminary in vivo studies show limited toxicity for some compounds. The company is preparing for first-in-human trials targeting novel DDR proteins such as RPA.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Indiana University School of Medicine research collaboration via co-founder Dr. John Turchi’s lab.Indiana Biosciences Research Institute membership and collaboration through Quantum Leap Award program, including access to Roche Diagnostics resources and IBRI facilities.
Beyond the preview
Go deeper on NERx Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NERx Biosciences.